Core Viewpoint - Innovent Biologics has entered into an $11.4 billion partnership with Takeda Pharmaceutical to enhance the development of its immuno-oncology and antibody-drug conjugate therapies [1] Company Summary - The deal with Takeda is aimed at accelerating the development of Innovent's immuno-oncology and antibody-drug conjugate products [1] - This collaboration signifies a strategic move for Innovent to leverage Takeda's expertise and resources in the pharmaceutical sector [1] Industry Summary - The partnership highlights the growing trend of collaborations in the biopharmaceutical industry, particularly in the fields of immuno-oncology and targeted therapies [1] - Such large-scale deals reflect the increasing investment and interest in innovative cancer treatments within the global pharmaceutical market [1]